Dr Flemming Ørnskov

Chairman of the Supervisory Board

Global President, Pharmaceuticals of Bausch & Lomb

Dr Flemming Ørnskov has been Chairman of the Supervisory Board of Evotec since August 2008. He is a well known executive with extensive experience within the pharmaceutical industry. As Global President of Pharmaceuticals at Bausch & Lomb, Dr Ørnskov is responsible for the company's prescription ophthalmic pharmaceuticals and generics, as well as its OTC business.

Most recently, Dr Ørnskov was CEO and President of LifeCycle Pharma, an emerging cardiovascular and transplantation specialty company. Prior, he served as CEO and President of biotech start-up Ikaria, Inc., which was sold to a private equity company within a year of him taking office. From 2002 to 2005, he was President of the Ophthalmics Business Unit for Novartis and from 2001 to 2002, he led Novartis' US cardiovascular franchise. Prior to joining Novartis, Dr Ørnskov held multiple leadership positions at Merck & Co.

Dr Ørnskov serves on several boards, and is Chairman of the board for Santaris Pharma A/S and Astion Pharma A/S.

Dr Ørnskov received a MD degree from University of Copenhagen, a MBA degree from INSEAD and a Master of Public Health degree from Harvard University.